Overview
The goal of this observational study is to test the association between high levels of Galectin-3 and the occurrence of post-operative atrial fibrillation after isolated coronary artery bypass grafting (CABG). The main question[s] it aims to answer are:
- Is Galectin-3 an accurate biomarker to predict higher risk of developing post-operative atrial fibrillation?
- Are high levels of Galectin-3 associated to other post-operative complications and major adverse cardiovascular events? Participants will be enrolled during pre-operative evaluation and a peripheral blood sample collection will be performed in the 24h before CABG. Participants will then be followed for a period of 12 months (daily during hospitalization and 3 appointments after hospital discharge) to determine whether patients with higher levels of Galectin-3 will have worse outcomes.
Description
Prospective, observational, single-center cohort study including patients undergoing coronary artery bypass graft (CABG) surgery.
Patients will be enrolled during preoperative evaluation. A peripheral blood sample will be collected within 24 hours before surgery and patients will be followed during hospitalization and for 12 months after discharge.
Eligibility
Inclusion Criteria:
- Patients undergoing coronary artery bypass graft surgery
Exclusion Criteria:
- Inability to sign the free and informed consent form
- Renal dysfunction with estimated glomerular filtration rate less than 30ml / min / 1.73m² or dialysis therapy
- Moderate to severe left ventricular dysfunction (ejection fraction < 40%)
- Patients with previous atrial fibrillation
- Pregnancy
- Concomitant valve surgery